Climb Bio (NASDAQ:CLYM) Shares Up 6.5% – Time to Buy?

Posted by Brenda Bartman on Oct 20th, 2026

Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) shares were up 6.5% during mid-day trading on Tuesday. The company traded as high as $10.21 and last traded at $10.3640. Approximately 77,227 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 1,040,872 shares. The stock had previously closed at $9.73.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CLYM. Mizuho upgraded shares of Climb Bio to a “strong-buy” rating in a research note on Wednesday, September 16th. Piper Sandler set a $40.00 price objective on shares of Climb Bio and gave the company an “overweight” rating in a research note on Thursday, September 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a report on Thursday. Robert W. Baird raised their price objective on shares of Climb Bio from $21.00 to $25.00 and gave the stock an “outperform” rating in a report on Thursday, September 3rd. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $34.00 target price on shares of Climb Bio in a research report on Monday, October 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $27.64.

View Our Latest Report on CLYM

Climb Bio Trading Up 9.7%

The company has a 50-day moving average of $13.65 and a 200-day moving average of $12.04. The firm has a market capitalization of $612.88 million, a price-to-earnings ratio of -12.92 and a beta of -0.04.

Climb Bio (NASDAQ:CLYM – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. On average, research analysts forecast that Climb Bio, Inc. will post -0.78 earnings per share for the current year.

Insider Buying and Selling at Climb Bio

In related news, Director Stephen Thomas sold 100,000 shares of Climb Bio stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total value of $1,367,000.00. Following the sale, the director directly owned 467,969 shares in the company, valued at $6,397,136.23. This trade represents a 17.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in Climb Bio in the 2nd quarter worth about $30,708,000. Braidwell LP increased its stake in shares of Climb Bio by 102.6% in the second quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock valued at $40,411,000 after purchasing an additional 1,569,352 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Climb Bio in the second quarter valued at approximately $10,727,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Climb Bio in the second quarter valued at approximately $7,348,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Climb Bio during the second quarter valued at approximately $2,148,000. 69.76% of the stock is owned by institutional investors and hedge funds.

About Climb Bio

(Get Free Report)

Climb Bio, Inc is a clinical-stage biotechnology company focused on developing novel therapies for patients with immune-mediated diseases, including autoimmune disorders. The company’s research is centered on addressing underlying drivers of abnormal immune activity and developing treatments intended to provide durable disease control.

Climb Bio’s activities include the discovery, development and clinical evaluation of investigational biologic medicines. Its programs are designed to target pathways involved in B-cell function, autoantibody production and other mechanisms that contribute to autoimmune disease.